Treatment outcomes of adult patients with recurrent tuberculosis in relation to HIV status in Zimbabwe: a retrospective record review

BMC Public Health

Owen Mugurungi³  Charles Sandy³  Tsitsi Mutasa-Apollo³  Satyanarayana Srinath¹  Anthony D Harries²  Kudakwashe C Takarinda³ 

[1] International Union Against Tuberculosis and Lung Disease, South-East Asian Union Office, C-6, Qutub Institutional Area, New Delhi, India;Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WCE1E 7HT, UK;AIDS & TB Unit, Ministry of Health & Child Welfare, 2nd Floor, Mkwati Building, Corner Livingstone Avenue and Fifth Street, Harare, Zimbabwe

关键词: Zimbabwe;    Treatment outcomes;    Recurrent tuberculosis;    HIV;   

Others  :  1163851
DOI  :  10.1186/1471-2458-12-124

 received in 2011-08-24, accepted in 2012-02-13,  发布年份 2012

【 摘 要 】

Background

Zimbabwe is a Southern African country with a high HIV-TB burden and is ranked 19^th among the 22 Tuberculosis high burden countries worldwide. Recurrent TB is an important problem for TB control, yet there is limited information about treatment outcomes in relation to HIV status. This study was therefore conducted in Chitungwiza, a high density dormitory town outside the capital city, to determine in adults registered with recurrent TB how treatment outcomes were affected by type of recurrence and HIV status.

Methods

Data were abstracted from the Chitungwiza district TB register for all 225 adult TB patients who had previously been on anti-TB treatment and who were registered as recurrent TB from January to December 2009. The Chi-square and Fischer's exact tests were used to establish associations between categorical variables. Multivariate relative risks for associations between the various TB treatment outcomes and HIV status, type of recurrent TB, sex and age were calculated using Poisson regression with robust error variance.

Results

Of 225 registered TB patients with recurrent TB, 159 (71%) were HIV tested, 135 (85%) were HIV-positive and 20 (15%) were known to be on antiretroviral treatment (ART). More females were HIV-tested (75/90, 83%) compared with males (84/135, 62%). There were 103 (46%) with relapse TB, 32 (14%) with treatment after default, and 90 (40%) with "retreatment other" TB. There was one failure patient. HIV-testing and HIV-positivity were similar between patients with different types of TB. Overall, treatment success was 73% with transfer-outs at 14% being the most common adverse outcome. TB treatment outcomes did not differ by HIV status. However those with relapse TB had better treatment success compared to "retreatment other" TB patients, (adjusted RR 0.81; 95% CI 0.68 - 0.97, p = 0.02).

Conclusions

No differences in treatment outcomes by HIV status were established in patients with recurrent TB. Important lessons from this study include increasing HIV testing uptake, a better understanding of what constitutes "retreatment other" TB, improved follow-up of true outcomes in patients who transfer-out and better recording practices related to HIV care and treatment especially for ART.

【 授权许可】

   
2012 Takarinda et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organisation Global tuberculosis control: WHO Report 2010 Geneva; 2010.
• [2]Harries AD, Maher D: TB/HIV A clinical manual. Geneva: World Health Organisation; 1996.
• [3]Corbett EL, Watt CJ, Walker N, Maher D, William BG, Raviglione MC, Dye C: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(Suppl 9):1009-1021.
• [4]Jasmer R, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ: Tuberculosis Trials Consortium: Recurrent Tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004, 170(Suppl 12):1360-1366.
• [5]Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, Fine PE, Glynn JR: Recurrent TB: relapse or reinfecion? The effect of HIV in a general population cohort in Malawi. AIDS 2010, 24(Suppl 3):417-426.
• [6]Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P: HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001, 358:1687-1693.
• [7]Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, Machiels L, Steenbergen G, Pobee JOM, Nunn P, McAdam KPW: The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995, 98:9-21.
• [8]Fitzpatrick LK, Okwera A, Mugerwa R, Ridzon R, Ehiner J, Onorato I: An investigation of suspected exogeneous reinfection in tuberculosis patients in Kampala, Uganda. Int J Tuberc Lung Dis 2002, 6(Suppl 6):550-552.
• [9]Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, Ramachandran R, Locht C, Jawahar MS, Narayanan PR: Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010, 201(Suppl 5):691-703.
• [10]Korenromp EL, Scano F, Williams BG, Dye C, Nunn P: Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: An analytical Review. Clin Infect Dis 2003, 37(Suppl 1):101-112.
• [11]Odendal L: Timing of ART initiation during TB treatment may not have significant impact on risk of death. [http://www.aidsmap.com/page/1439095/] webcite
• [12]Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, Salaniponi FM, Harries AD: Voluntary counseling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003, 17(Suppl 7):1053-1061.
• [13]Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q: Starting ARV therapy at three points in TB therapy. N Engl J Med 2010, 362:697-706.
• [14]Raizada N, Chauhan LS, Babu BS, Thakur R, Khera A, Wares DF, Suvanand S, Bachani D, Rewari BB, Dewan PK: Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India. PLoS One 2009, 4(6):e5999.
• [15]Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S: Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):42-46.
• [16]Chitungwiza informations. City Chitungwiza in Zimbabwe [http://athaia.org/Zimbabwe/chitungwiza.html] webcite
• [17]Ministry of Health and Child Welfare: Zimbabwe National Tuberculosis Control Programme Manual. 3rd edition. Harare, Zimbabwe: Ministry of Health and Child Welfare; 2007.
• [18]Ministry of Health and Child Welfare: National HIV Testing and Counselling Training Manual. Harare, Zimbabwe: Ministry of Health and Child Welfare; 2007.
• [19]Ministry of Health and Child Welfare: National Guidelines for TB/HIV Co-management. Harare, Zimbabwe: Ministry of Health and Child Welfare; 2009.
• [20]Ministry of Health and Child Welfare, National Drug and Therapeutics Policy Advisory Committee: Guidelines for antiretroviral therapy in Zimbabwe. Harare, Zimbabwe: Ministry of Health and Child Welfare; 2007.
• [21]Zou G: A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159(Suppl 7):702-706.